The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: A systematic review and meta-analysis of observational research

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cao, Chao ^a   Wu, Yinfang ^a   Xu, Zhiwei ^a   Lv, Dan ^a   Zhang, Chao ^a   Lai, Tianwen ^a   Li, Wen ^a   Shen, Huahao ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b State Key Laboratory of Respiratory Diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLICATION; DISEASE COURSE; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; PROGNOSIS; PUBLISHING; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DISEASE PROGRESSION; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROGNOSIS; PUBLICATION BIAS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84946721243     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16461     Document Type: Article

References (42)

1. Baigent C. et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366, 1267-78 (2005).
2. Liao J. K. & Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118 (2005).
3. Ishida W. et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku. J. Exp. Med. 212, 265-73 (2007).
4. Cazzola M., Matera M. G., Rogliani P. & Page C. Treating systemic effects of COPD. Trends. Pharmacol. Sci. 28, 544-50 (2007).
5. Young R. P., Hopkins R. & Eaton T. E. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 85, 414-21 (2009).
6. van Gestel Y. R. et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am. J. Cardiol. 102, 192-6 (2008).
7. Sheng X. et al. Effect of statins on total cholesterol concentrations, cardiovascular morbidity, and all-cause mortality in chronic obstructive pulmonary disease: a population-based cohort study. Clin. Ther. 34, 374-84 (2012).
8. Ekström M. P., Hermansson A. B. & Ström K. E. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 187, 715-20 (2013).
9. Lawes C. M. et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care. Respir. J. 21, 35-40 (2012).
10. Søyseth V., Brekke P. H., Smith P. & Omland T. Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 29, 279-83 (2007).
11. Bartziokas K. et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm. Pharmacol. Ther. 24, 625-31 (2011).
12. Lahousse L. et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm. Pharmacol. Ther. 26, 212-7 (2013).
13. Mortensen E. M. et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 10, 45 (2009).
14. Mancini G. B. et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 47, 2554-60 (2006).
15. Frost F. J., Petersen H. & Tollestrup K. & Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 131, 1006-12 (2007).
16. van Gestel Y. R. et al. COPD and cancer mortality: the influence of statins. Thorax. 64, 963-7 (2009).
17. Wang M. T. et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 126, 598-606.e2 (2013).
18. Blamoun A. I. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 62, 1373-8 (2008).
19. Huang C. C. et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study in Taiwan. Clin. Ther. 33, 1365-70 (2011).
20. Ozyilmaz E., Kokturk N., Teksut G. & Tatlicioglu T. Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease. Int. J. Clin. Pract. 67, 691-7 (2013).
21. Ou X. M. et al. Simvastatin attenuates experimental small airway remodelling in rats. Respirology. 14, 734-45 (2009).
22. Chen Y. J. et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signalregulated kinase pathway. Int. Immunopharmacol. 10, 685-693 (2010).
23. Janda S., Park K., FitzGerald J. M., Etminan M. & Swiston J. Statins in COPD: a systematic review. Chest. 136, 734-43 (2009).
24. Dobler C. C., Wong K. K. & Marks G. B. Associations between statins and COPD: a systematic review. BMC. Pulm. Med. 9, 32 (2009).
25. Criner G. J. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Engl. J. Med. 370, 2201-10 (2014).
26. Mapel D. W., Dedrick D. & Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD. 2, 35-41 (2005).
27. Anthonisen N. R., Connett J. E., Enright P. L. & Manfreda J. Lung Health Study Research Group: Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care. Med. 166, 333-9 (2002).
28. Lee T. M., Lin M. S. & Chang N. C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am. J. Cardiol. 101, 530-5 (2008).
29. Rezk N. A. & Elewa A. Anti inflammatory effects of statin in COPD. Egypt. J. Chest. Dis. Tuberc. 62, 65-9 (2013).
30. Undas A. et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb. Haemost. 102, 1176-82 (2009).
31. Hakamada-Taguchi R. et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res. 93, 948-56 (2003).
32. Reed R. M. et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD. 8, 96-102 (2011).
33. Lee T. M., Chen C. C., Shen H. N. & Chang N. C. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin. Sci (Lond). 116, 497-505 (2009).
34. Chaouat A., Naeije R. & Weitzenblum E. Pulmonary hypertension in COPD. Eur. Respir. J. 32, 1371-85 (2008).
35. Beri A., Sural N. & Mahajan S. B. Non-atheroprotective effects of statins: a systematic review. Am. J. Cardiovasc. Drugs. 9, 361-70 (2009).
36. Horita N. et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and metaanalysis of observational studies. Respir. Res. 15, 80 (2014).
37. Moher D., Liberati A., Tetzlaff J. & Altman D. G. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS. Med. 6, e1000097 (2009).
38. Stroup D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 283, 2008-12 (2000).
39. Wells G. A., de Sousa M. R., Fereguetti T. O. & Rabello A. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.http://www.ohri.ca/programs/clinical-epidemiology/oxford.htmAccessed. (Date of access: 2 Apr 2012).
40. Downs S. H. & Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Community. Health. 52, 377-84 (1998).
41. Higgins J. P., Thompson S. G., Deeks J. J. & Altman D. G. Measuring inconsistency in meta-analyses. BMJ. 327, 557-60 (2003).
42. Egger M., Davey Smith G., Schneider M. & Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315, 629-34 (1997).